Sarepta Therapeutics (SRPT) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free SRPT Stock Alerts $132.74 +0.24 (+0.18%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 12:43 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Fiera Capital CorpFiera Capital Corp cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 348,212 shares of the biotechnology company's stock after selling 8,111 shares duriMay 16 at 3:32 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Lifted to Outperform at OppenheimerMay 15 at 5:40 PM | marketbeat.com203,882 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by First Turn Management LLCFirst Turn Management LLC bought a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 203,882 shares of the biotechnology company's stock, vMay 14 at 5:18 PM | marketbeat.comNicholas Investment Partners LP Sells 2,084,756 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Nicholas Investment Partners LP lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 99.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,329 shares of the biotechnology companyMay 14 at 3:34 PM | msn.comRoblox downgraded, Western Digital initiated: Wall Street's top analyst callsMay 14 at 3:34 PM | msn.comOppenheimer Upgrades Sarepta Therapeutics (SRPT)May 14 at 10:34 AM | msn.comSarepta upgraded at Oppenheimer on potential Elevidys label expansionMay 14 at 8:58 AM | marketbeat.comOppenheimer Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to "Outperform"Oppenheimer raised shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $180.00 target price on the stock in a research note on Tuesday.May 11, 2024 | marketbeat.comSwiss National Bank Sells 17,800 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Swiss National Bank lowered its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 10.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 156,283 shares of the biotechnology company's stock afMay 7, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Dallan Murray Sells 3,635 SharesMay 6, 2024 | marketbeat.comInsider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells 3,635 Shares of StockSarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) insider Dallan Murray sold 3,635 shares of the business's stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares in the company, valued at $2,537,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.May 5, 2024 | marketbeat.com10,146 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Acquired by Sapient Capital LLCSapient Capital LLC purchased a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,146 shares of the biotechnology company's stock,May 5, 2024 | finance.yahoo.comEarnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMay 4, 2024 | investorplace.com3 Biotech Stocks With the Potential to Make You an Overnight MillionaireMay 4, 2024 | marketbeat.comVan ECK Associates Corp Has $7.90 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Van ECK Associates Corp cut its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 15.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 81,955 shares of the biotechnology company's stock after selling 14,510May 3, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $175.00JPMorgan Chase & Co. dropped their price objective on Sarepta Therapeutics from $177.00 to $175.00 and set an "overweight" rating for the company in a report on Friday.May 3, 2024 | bizjournals.comDrug watchdog criticizes Sarepta gene therapy approval, costMay 3, 2024 | finance.yahoo.comGene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global HealthMay 3, 2024 | businesswire.comGene Therapy Pioneer Jerry R. Mendell, M.D.May 3, 2024 | marketbeat.comBrokers Issue Forecasts for Sarepta Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:SRPT)Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Analysts at Leerink Partnrs increased their Q3 2024 earnings per share estimates for Sarepta Therapeutics in a note issued to investors on Wednesday, May 1st. Leerink Partnrs analyst J. Schwartz now anticipates that the biotechnology companMay 2, 2024 | msn.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Affirmed Amid Elevidys Regulatory Progress and Portfolio StrengthMay 2, 2024 | benzinga.comWhat Analysts Are Saying About Sarepta Therapeutics StockMay 2, 2024 | msn.comSarepta Elevidys accelerated approval criticized by ICER execMay 2, 2024 | finance.yahoo.comSarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley SaysMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Amid Anticipated Label Expansion for ElevidysMay 2, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Neutral Rating for Sarepta Therapeutics (NASDAQ:SRPT)Cantor Fitzgerald reiterated a "neutral" rating and issued a $128.00 target price on shares of Sarepta Therapeutics in a report on Thursday.May 2, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Better-Than-Expected EarningsSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Strong EarningsMay 2, 2024 | finance.yahoo.comQ1 2024 Sarepta Therapeutics Inc Earnings CallMay 2, 2024 | marketbeat.comCalifornia Public Employees Retirement System Sells 38,071 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)California Public Employees Retirement System lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 23.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 126,386 shares oMay 2, 2024 | finance.yahoo.comSarepta Therapeutics Inc (SRPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...May 2, 2024 | gurufocus.comQ1 2024 Sarepta Therapeutics Inc Earnings Call TranscriptMay 1, 2024 | msn.comSarepta Therapeutics (SRPT) Q1 2024 Earnings Call TranscriptMay 1, 2024 | investorplace.comSRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | markets.businessinsider.comSarepta Therapeutics Q1 Earnings SummaryMay 1, 2024 | finance.yahoo.comSarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate DevelopmentsMay 1, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Releases Quarterly Earnings Results, Beats Estimates By $0.84 EPSSarepta Therapeutics (NASDAQ:SRPT - Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same period in the prior year, the firm earned ($1.44) EPS. The business's revenue was up 63.1% on a year-over-year basis.May 1, 2024 | marketbeat.comResearch Analysts Offer Predictions for Sarepta Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:SRPT)Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Zacks Research lowered their Q2 2024 EPS estimates for shares of Sarepta Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn ($0.06) per shareApril 30, 2024 | businesswire.comSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | markets.businessinsider.comHere's what to expect from Sarepta Therapeutics's earnings reportApril 30, 2024 | marketbeat.comQ3 2024 EPS Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Boosted by AnalystSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Investment analysts at Zacks Research raised their Q3 2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors on Monday, April 29th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company wApril 26, 2024 | bizjournals.comState’s highest paid CEO reports major drop in compensationApril 26, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Sigma Planning CorpSigma Planning Corp lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 58.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,213 shares of the biotechnology company's stockApril 25, 2024 | marketbeat.comSemanteon Capital Management LP Purchases New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Semanteon Capital Management LP purchased a new stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 13,120 shares of the biotechnology company's stock, valued at apApril 25, 2024 | marketbeat.comSarepta Therapeutics (SRPT) Scheduled to Post Earnings on WednesdaySarepta Therapeutics (NASDAQ:SRPT) will be releasing earnings after the market closes on Wednesday, May 1, Zacks reports.April 25, 2024 | finance.yahoo.comBullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of StockApril 25, 2024 | marketbeat.comZacks Research Equities Analysts Decrease Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities researchers at Zacks Research reduced their FY2026 earnings per share estimates for shares of Sarepta Therapeutics in a research note issued on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now forecasts that the biotechnoApril 24, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Up 5.9%Sarepta Therapeutics (NASDAQ:SRPT) Trading 5.9% HigherApril 24, 2024 | businesswire.comSarepta Therapeutics to Announce First Quarter 2024 Financial ResultsApril 24, 2024 | marketbeat.comQ1 2026 EPS Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Cut by AnalystSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Analysts at Zacks Research decreased their Q1 2026 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company wil Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision. Start streaming it now at no cost here SRPT Media Mentions By Week SRPT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼1.050.55▲Average Medical News Sentiment SRPT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼119▲SRPT Articles Average Week Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Dr. Reddy's Laboratories News Today United Therapeutics News Today Viatris News Today BeiGene News Today Catalent News Today Teva Pharmaceutical Industries News Today BioMarin Pharmaceutical News Today Roivant Sciences News Today Viking Therapeutics News Today Legend Biotech News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyThe 1,000X Crypto PlaybookTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
